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Abstract 
Background: Placental malaria is associated with increased risk of adverse perinatal outcomes. While primigravidity 
has been reported as a risk factor for placental malaria, little is known regarding the relationship between gravidity, 
symptomatology and timing of Plasmodium falciparum infection and the development of placental malaria.
Methods: The aim of this study was to investigate the relationship between the development of placental malaria 
and gravidity, timing of infection, and presence of symptoms. This is a secondary analysis of data from a double-blind 
randomized control trial of intermittent preventive therapy during pregnancy in Uganda. Women were enrolled from 
12 to 20 weeks gestation and followed through delivery. Exposure to malaria parasites was defined as symptomatic 
(fever with positive blood smear) or asymptomatic (based on molecular detection of parasitaemia done routinely 
every 4 weeks). The primary outcome was placental malaria diagnosed by histopathology, placental blood smear, 
and/or placental blood loop-mediated isothermal amplification. Multivariate analyses were performed using logistic 
regression models. Subgroup analysis was performed based on the presence of symptomatic malaria, gravidity, and 
timing of infection.
Results: Of the 228 patients with documented maternal infection with malaria parasites during pregnancy, 101 
(44.3%) had placental malaria. Primigravidity was strongly associated with placental malaria (aOR 8.90, 95% CI 4.34–
18.2, p < 0.001), and each episode of malaria was associated with over a twofold increase in placental malaria (aOR 
2.35, 95% CI 1.69–3.26, p < 0.001). Among multigravid women, the odds of placental malaria increased by 14% with 
each advancing week of gestation at first documented infection (aOR 1.14, 95% CI 1.02–1.27, p = 0.02). When stratified 
by the presence of symptoms, primigravidity was only associated with placental malaria in asymptomatic women, 
who had a 12-fold increase in the odds of placental malaria (aOR 12.19, 95% CI 5.23–28.43, p < 0.001).
Conclusions: Total number of P. falciparum infections in pregnancy is a significant predictor of placental malaria. The 
importance of timing of infection on the development of placental malaria varies based on gravidity. In primigravidas, 
earlier asymptomatic infections were more frequently identified in those with placental malaria, whereas in multi-
gravidas, parasitaemias detected later in gestation were associated with placental malaria. Earlier initiation of an effec-
tive intermittent preventive therapy may help to prevent placental malaria and improve birth outcomes, particularly 
in primigravid women.
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Background
Infection with malaria parasites during pregnancy is 
associated with increased risk of maternal and neo-
natal morbidity and mortality. In sub-Saharan Africa, 
where an estimated 11 million pregnancies are affected 
by malaria infection [1], malaria is thought to cause up 
to 100,000 infant deaths each year, the majority of which 
are secondary to prematurity, low birth weight, and neo-
natal anaemia [2, 3]. A unique characteristic of Plasmo-
dium falciparum is the ability of infected erythrocytes to 
sequester in the placenta, leading to inflammation and 
adverse birth outcomes [4]. Placental malaria has been 
associated with increased risks of adverse obstetric out-
comes including maternal anaemia, preterm delivery, 
fetal growth restriction, low birth weight, and maternal 
and neonatal mortality [5–7].
Previous studies have shown that primigravidity is a 
risk factor for placental malaria and resulting obstet-
ric morbidity [8, 9]. A prior analysis of this study cohort 
found that placental malaria was more likely in women 
with high malaria burden (defined as ≥ 2 episodes of 
symptomatic malaria or ≥ 50% positive loop-mediated 
isothermal amplification (LAMP) samples) and was asso-
ciated with increased rates of preterm birth and a trend 
towards higher rates of small for gestational age (SGA) 
neonates [10]. However, little is known about whether 
the effect of gravidity on placental malaria varies by 
timing and symptomatology of P. falciparum. A better 
understanding of how these factors influence placental 
infection in primigravid versus multigravid women may 
allow for more targeted public health interventions to 
reduce the prevalence of placental malaria and improve 
obstetric outcomes in both groups. Therefore, the main 
objective of this study was to assess whether the impact 
of gravidity on placental malaria varies by the presence of 
symptoms and/or timing of infection.
Methods
Study procedures
This was a secondary analysis of data collected from 
a double-blind, randomized trial of intermittent pre-
ventive therapy during pregnancy in Tororo, Uganda, 
a rural district in southeastern Uganda with an esti-
mated entomologic inoculation rate of 310 infectious 
bites per person-year [11]. Participants were enrolled 
from June to October 2014; the complete study protocol 
for the parent study has been described elsewhere [11]. 
Briefly, pregnant women were enrolled at 12–20  weeks 
gestation and randomized to preventive therapy with 
sulfadoxine-pyrimethamine given every 8  weeks, dihy-
droartemisinin–piperaquine given every 8  weeks, or 
dihydroartemisinin–piperaquine given every 4  weeks 
during pregnancy. All participants were at least 16 years 
of age and HIV-uninfected at the time of enrollment.
At study enrollment, participants were assessed with 
standardized history and physical exam including con-
firmation of gestational age (GA) by ultrasound. Routine 
visits were scheduled every 4 weeks and included collec-
tion of dried blood spots for loop-mediated isothermal 
amplification (LAMP). Study participant were encour-
aged to come the study clinic any time they were ill and 
if they presented with a documented fever (tympanic 
temperature ≥ 38.0  °C) or a reported history of fever 
within 24  h prior to presentation, peripheral blood was 
collected for a thick blood smear. If the thick smear was 
positive, the participant was diagnosed with sympto-
matic malaria and treated with artemether-lumefantrine. 
Because LAMP results were not available until after com-
pletion of the trial, women with asymptomatic parasitae-
mia did not receive treatment. For the purposes of this 
analysis, women who presented with fever, but later had 
a positive LAMP were considered to have asymptomatic 
parasitaemia.
Placental tissue for histopathology, placental blood 
for thick smears and LAMP were collected within 1 h of 
delivery. Women who delivered at home were visited by 
study staff as soon as possible after delivery for evalua-
tion and collection of specimens. Women with evidence 
of any infection with malaria parasites during pregnancy, 
known birth outcomes, and complete placental analy-
sis (including placental histopathology, placental blood 
microscopy, and placental blood LAMP) were included 
in this study. Plasmodium falciparum infection was 
defined as both symptomatic malaria (fever and positive 
thick smear) and/or asymptomatic parasitaemia (periph-
eral maternal parasitaemia by LAMP in the absence of 
symptoms). The primary outcome, placental malaria, was 
defined as any evidence of placental infection, including 
the presence of parasites or pigment by histopathology, 
parasites detected in placental blood by microscopy, or 
positive placental blood LAMP.
Laboratory methods
Dried blood spot samples were tested for P. falciparum 
DNA using LAMP at enrollment and every 4  weeks 
through pregnancy, as previously described [12, 13]. 
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Placental tissue samples were fixed with formalin and 
embedded in paraffin. They were then processed and 
examined by two independent readers using a standard-
ized case record form for histological evidence of placen-
tal malaria [11]. Any discrepancy between the readers 
was resolved by a third reader. Blood smears were stained 
with 2% Giemsa and evaluated by two trained laboratory 
technicians. A smear was considered negative if no asex-
ual parasites were detected in 100 high-powered fields. 
Any discrepancies were again resolved by a third reader.
Clinical variables of interest
Demographic data including maternal age, gravidity, 
body mass index (BMI), GA at enrollment and delivery, 
possession of bed net at enrollment, wealth status, and 
intermittent preventive therapy treatment arm were col-
lected. Wealth status was defined as lowest, middle, and 
highest tertiles at study enrollment based on a compos-
ite variable of land ownership and possession of several 
household items [11]. GA was established at enrollment 
by obstetric dating by last menstrual period and ultra-
sound confirmation per WHO guidelines [14]. Malaria 
infection during pregnancy was defined as both symp-
tomatic malaria and asymptomatic parasitaemia as pre-
viously mentioned, and longitudinal data on timing of 
infection during pregnancy were collected.
Birth outcomes including GA at delivery, birth-
weight, and fetal and neonatal survival to hospital dis-
charge were collected and reported in previous analysis 
of this data set [10]. Preterm delivery was defined as 
delivery at < 37  weeks GA. SGA was defined as birth-
weight < 10%ile for GA based on East African fetal weight 
standards [15] which have been shown to be more accu-
rate than other international growth standards in diag-
nosing SGA in this population [10, 16, 17]. For twin 
gestations, outcomes were considered positive if the out-
come was seen in at least one twin or placenta.
Statistical methods
Data analyses were performed using Stata 14 (Stata 
Corp, College Station, TX). Wilcoxon Rank Sum was 
used to compare median values of continuous vari-
ables, all of which were non-normally distributed. 
Chi squared and Fisher exact tests were used to com-
pare proportions. Multivariate binary logistic regres-
sion using placental malaria as the main outcome 
were performed and were adjusted for primigravid-
ity, GA at study enrollment, and GA at the time of the 
first recorded infection in pregnancy. Variables were 
included in the multivariate model if they were signifi-
cant in the univariate analysis. Multivariate analyses 
stratified by gravidity, symptomatology and GA at ini-
tial infection were performed to examine interactions 
between possible predictors. The decision to do strati-
fied analyses was made based on the a priori hypothesis 
that the relationship between these predictors could 
not be fully explained by multivariate analysis alone. All 




Of the 300 HIV-negative women enrolled in the parent 
trial, 289 (96.3%) were followed to delivery. Of these, nine 
(3.1%) were excluded for incomplete analyses for placen-
tal malaria including seven who did not have placental 
biopsies taken for histopathology and an additional two 
with missing results for placental blood analyses. Five 
women with placental malaria did not have documented 
evidence of parasitaemia prior to delivery and, given the 
inability to determine timing or number of infections, 
they were excluded from the analysis. Of the remaining 
275 women, 228 (82.9%) had evidence of infection with 
malaria parasites during pregnancy and were included 
in the analyses. Of these, 127/228 (55.7%) did not have 
evidence of placental malaria and 101/228 (44.3%) had 
placental malaria (Fig.  1). The number of participants 
diagnosed with placental malaria via each of the three 
methods used are displayed in Fig.  2. Histopathology, 
which also detects past placental malaria, was the most 
sensitive of the three methods.
The median age of study participants was 21.1  years, 
and 38.2 percent were primigravid. Demographic char-
acteristics and obstetrical outcomes of the study partici-
pants stratified by placental malaria status are presented 
in Table 1. Women with placental malaria were younger 
(19.0  years (17.9–21.3) vs. 22.7 (19.9–25.7); p < 0.01) 
(median (IQR)) and more likely to be primigravid (63.4% 
vs. 18.1%, p < 0.01). Those with placental malaria also 
enrolled (and therefore initiated intermittent preventive 
therapy) at a slightly later GA (15.3 weeks (14.0–17.6) vs. 
14.7 (13.6–15.9) weeks, p < 0.01) and were significantly 
more likely to have received sulfadoxine-pyrimethamine 
treatment as compared to dihydroartemisinin–pipe-
raquine (48.5% versus 31.5%, p ≤ 0.01). All of the included 
twin gestations (n = 4) had evidence of placental malaria 
in at least one placenta (Table 1). As previously reported 
[10], women with placental malaria delivered at an earlier 
GA (39.3 weeks (38.0–40.3) vs. 40.0 (39.0–40.9), p < 0.01) 
and were more likely to deliver preterm (< 37 weeks GA) 
(15.0% vs. 4.7%, p < 0.01) with correspondingly low birth 
weight (Table  1). Additionally, infants from pregnancies 
affected by placental malaria were more likely to be SGA 
(25.7% vs. 15.0%, p = 0.04). There were no significant dif-
ferences in fetal or neonatal survival between the groups.
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228 women with peripheral 
parasitemia included in final analyses
No Placental Malaria (n=127)
Symptomac or asymptomac infecon with 
confirmatory blood smear or laboratory 
evidence of malaria parasitemia by LAMP and 
no evidence of placental malaria
Placental Malaria (n=101)
Presence of parasites or pigment on 
histopathology, parasites on 
placental blood smear microscopy, or 
posive placental blood LAMP
386 women screened
86 excluded during screening
36 prior SP or anmalarial therapy during pregnancy
25 gestaonal age greater than 20 weeks
11 HIV positive
3 intenon of moving outside of study area
2 gestaonal age less than 12 weeks
2 chronic medical condion
2 less than 16 years of age
1 non-viable pregnancy 
1 early or acve labor
1 residence greater than 30 km from clinic
1 does not plan to deliver in the hospital
1 unwilling to avoid medicaons outside protocol
11 withdrawn before delivery
5 unable to locate for > 60 days
5 moved out of study area
1 became HIV-infected
9 incomplete sample for placental histopathology
300 women delivered
289 followed to delivery
47 no malaria diagnosed during pregnancy and all 
samples negave for malaria parasites by LAMP
5 diagnosed with placental malaria but no prior infecon
Fig. 1 Flowchart of study participants. This figure displays the process for selecting study participants and the number of participants excluded in 
each category. SP sulfadoxine-pyrimethamine, LAMP loop-mediated isothermal amplification
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Longitudinal measures of P. falciparum infection
Timing of initial documented infection and first episode 
of symptomatic malaria in women with and without pla-
cental malaria are depicted graphically in Fig. 3. Charac-
teristics of infection are compared by placental malaria 
status in Table  2. Any symptomatic malaria at any time 
during pregnancy was more common in patients with 
placental malaria than those without placental malaria 
(29.7% vs. 18.1%, p = 0.04). Of those with at least one 
episode of symptomatic malaria, those with placental 
malaria had their first episode of symptomatic malaria 
at a later GA as compared to those without placental 
malaria (24.0  weeks (18.9–28.3) vs. 18.3 (16.1–20.0), 
p ≤ 0.01). GA at first documented infection (including 
symptomatic and asymptomatic) was not statistically dif-
ferent between the two groups (p = 0.15) (Table 2). Primi-
gravidity, gestational age at enrollment, any symptomatic 
malaria during pregnancy and total number of times par-
asitaemia was detected in pregnancy were all controlled 
for in multivariate analyses because they were signifi-
cant in univariate analyses. Gestational age at first docu-
mented infection was included in multivariate modeling 
rather than GA at first symptomatic infection to allow for 
examination of timing of infection without overfitting for 
symptomatology. In multivariate analyses, primigravidity, 
later GA at enrollment and increasing frequency of infec-
tions detected during pregnancy remained strongly asso-
ciated with development of placental malaria (aOR 9.06, 
95% CI 4.38–18.71, p < 0.001; aOR 1.24, 95% CI 1.02–
1.50, p = 0.03; aOR 2.21, 95% CI 1.67–2.93, p < 0.001, 
respectively) (Table  3).  As primigravid women are at 
increased risk of malaria infection, we also conducted the 
multivariate analysis without controlling for  total num-
ber of infections in pregnancy in the model (Additional 
file  1: Table  S1).  Overall trends and statistical signifi-
cance of findings for primigravidity and gestational age at 
enrollment were unchanged, and GA of first documented 
infection remains statistically insignificant. Any symp-
tomatic malaria during pregnancy became  statistically 
significant.   
Subgroup analyses
In primigravidas, each additional week of GA at enroll-
ment was associated with an increase in the odds of pla-
cental malaria (aOR 1.84, 95% CI 1.21–2.78, p < 0.01), but 
this association was not seen in multigravidas. In multi-
gravid women, each additional week of gestation at ini-
tial detected infection was associated with a 1.12-fold 
increase in odds of placental malaria (aOR 1.12, 95% CI 
1.02–1.24, p = 0.02). This trend was not seen in primi-
gravidas. Total number of times infection was detected 
in pregnancy remained strongly associated with placen-
tal malaria in both primigravid and multigravid women 
(Table 4 and Fig. 4).
Multivariate analyses stratified by presence of any 











Fig. 2 Number of placental malaria infections diagnosed by each method. The yellow circle holds women diagnosed by placental histopathology. 
The blue circle indicates diagnosis via placental blood microscopy, and the green circle represents diagnosis via placental blood LAMP
Page 6 of 11Tran et al. Malar J          (2020) 19:227 
was also performed. In women with only asymptomatic 
parasitaemia, primigravidity was associated with over a 
12-fold increase in odds of developing placental malaria 
(aOR 12.07, 95% CI 5.24–27.81, p < 0.001), while there 
was no statistically significant association between primi-
gravidity and placental malaria among those with any 
symptomatic malaria. In both groups, total number of 
infections in pregnancy remained highly associated with 
placental malaria (Table 5).
Lastly, multivariate analyses were stratified by GA 
at initial documented infection. These categories were 
selected based on timing of enrollment in the study and 
subsequent testing: < 14  weeks (enrollment in first tri-
mester), 14–19.9  weeks (enrollment in second trimes-
ter), and ≥ 20  weeks gestation (infection after study 
enrollment). Primigravidity was strongly associated with 
placental malaria in women whose initial documented 
infection occurred prior to 14  weeks (aOR 29.30, 95% 
CI 3.95–217.5, p = 0.001), as well as in women whose 
first infection occurred between 14 and 19.9  weeks 
(aOR 10.63, 95% CI 4.12–27.42, p < 0.001). Primigravid-
ity was not a significant predictor of placental malaria 
in women whose initial infection occurred at or beyond 
20 weeks gestation. Total number of times infection was 
detected in pregnancy, however, was strongly associated 
with placental malaria in women whose first infection 
occurred at or beyond 20 weeks (aOR 5.61, 95% CI 1.59–
19.78, p < 0.01) as well as in women whose first infection 
occurred between 14 and 20 weeks gestation (aOR 2.63, 
95% CI 1.80–3.87, p < 0.001) (Table 6).
Discussion
Principal findings
This study finds that the impact of gravidity on devel-
opment of placental malaria varies by symptomatology 
and timing of P. falciparum infection. In women with 
only asymptomatic parasitaemia, primigravidity was 
the strongest predictor of placental malaria. In con-
trast, among women with symptomatic malaria, pla-
cental malaria was not significantly associated with 
Table 1 Characteristics of study participants by placental malaria status
BMI body mass index, GA gestational age, SGA small for gestational age
Statistically significant p values (< 0.05) are indicated in italics
a Information missing for 1 patient
b Defined as birthweight < 2500 g
c Defined as birthweight < 10%ile for GA based on East African growth standards.15
d Data unavailable for four patients including two in the peripheral malaria group and 2 in the placental malaria group
Data are presented as median (interquartile range) or n (%). Wilcoxon Rank Sum and Chi squared or Fischer Exact tests were used to compare nonparametric 
continuous variables and proportions, respectively. Pregnancies with peripheral malaria only (without placental malaria) and pregnancies with placental malaria are 
the comparison groups for the p values
Variable Placental malaria status in pregnancy
No placental malaria (n = 127) Placental malaria (n = 101) p value
Maternal age, years 22.7 (19.9–25.7) 19.0 (17.9–21.3) < 0.001
Primigravid 23 (18.1) 64 (63.4) < 0.001
BMI, kg/m2 20.6 (19.0–22.2) 21.0 (19.7–22.7) 0.08
Twin  gestationa 0 (0.0) 4 (4.0) 0.04
GA at enrollment, weeks 14.7 (13.6–15.9) 15.3 (14.0–17.6) 0.003
Household wealth index 0.80
 Lowest tertile 46 (36.2) 37 (36.6)
 Middle tertile 42 (33.1) 37 (36.6)
 Highest tertile 39 (30.7) 27 (26.7)
Intermittent preventive therapy drug 0.01
 Sulfadoxine-pyrimethamine 40 (31.5) 49 (48.5)s
 Dihydroartemisinin-piperaquine 87 (68.5) 52 (51.5)
GA at delivery, weeks 40.0 (39.0–40.9) 39.3 (38.0–40.3) < 0.001
Preterm birth < 37 weeks GA 6 (4.7) 15 (14.9) 0.01
Very preterm birth < 32 weeks GA 1 (0.8) 4 (4.0) 0.17
Low birth  weightb 10 (7.9) 19 (18.8) 0.01
Small for gestational  agec 19 (15.0) 26 (25.7) 0.04
Stillbirth 0 (0.0) 2 (2.0) 0.09
Neonatal  demised (N = 224) 4 (3.2) 0 (0.0) 0.13
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gravidity. In regards to timing of infection, the magni-
tude of the association between primigravidity and the 
odds of placental malaria increased the earlier infec-
tion with malaria parasites was first detected, while 
multigravidity was associated with higher odds of pla-
cental malaria when infection occurred later in preg-
nancy. Of note, because the study population is women 
infected with malaria in pregnancy, the odds ratios 
Fig. 3 Timing of infection by malaria status and gravidity. a Shows the number (label) and percent of the total cohort (y-axis) of women whose 
initial documented infection occurred within each gestational age category separated for individuals with no placental malaria (black) and placental 
malaria (grey). b presents these data on initial symptomatic infection among symptomatic women. c Presents data for primigravid women only, 
while d presents data for multigravid women only. p-values are two-way and calculated with Chi squared analysis
Table 2 Measures of malaria infection, by placental malaria status
GA gestational age, LAMP loop mediated isothermal amplification
Data are presented as median (interquartile range) or n (%). Wilcoxon Rank Sum and Chi squared tests were used to compare nonparametric continuous variables and 
proportions, respectively
Statistically significant p values (< 0.05) are indicated in italics
a No patients had symptomatic malaria at the time of enrollment
Variable Placental malaria status in pregnancy
No placental malaria (n = 127) Placental malaria (n = 101) p value
Positive LAMP at  enrollmenta 84 (66.1) 76 (75.3) 0.14
Number of times parasitaemia detected per pregnancy 2.0 (2.0–3.0) 3.0 (2.0–5.0) < 0.001
Any symptomatic malaria during pregnancy 23 (18.1) 30 (29.7) 0.04





GA at initial documented parasitaemia, weeks 15.9 (14.3–17.9) 16.1 (14.7–18.6) 0.15
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reported in this study do not reflect odds of placental 
malaria in the general population, but rather odds of 
developing placental malaria if infected with P. falcipa-
rum in pregnancy.
When stratified by maternal gravidity, there were dif-
ferences in the impact of timing of initial P. falciparum 
infection on the development of placental malaria. In 
multigravid women, later GA at initial infection is more 
strongly associated with placental malaria, while this is 
not observed in primigravid women. This suggests that 
much of the increased risk for primigravid women lies 
in early infection, which is not the case in multigravi-
das. This is consistent with the finding that later enroll-
ment (and initiation of intermittent preventive therapy) 
increased odds of placental malaria in primigravid 
women but not in multigravid women.
This is the first study to explore the relationships 
between gravidity, symptomatology and timing of infec-
tion and the development of placental malaria. Prior lit-
erature on how the presence of malaria symptoms during 
pregnancy affects development of placental malaria is 
sparse. However, one cross sectional study of nulliparous 
Nigerian women found that more than 60% of asympto-
matic women had evidence of placental parasitaemia at 
delivery, demonstrating that even asymptomatic infec-
tion has the potential to significantly impact obstetric 
outcomes [18]. This study adds to the current literature 
by highlighting that primigravid women are particularly 
vulnerable to placental malaria even when malaria infec-
tion remains clinically asymptomatic.
Table 3 Predictors of placental malaria
GA gestational age
Statistically significant p values (< 0.05) are indicated in italics
Multivariate binary logistic regression using placental malaria as the main 
outcome were performed and were adjusted for primigravidity, GA at study 
enrollment, any symptomatic malaria during pregnancy, GA of first documented 
infection, and total number of malaria infections (symptomatic and/or 
asymptomatic) in pregnancy. Variables were kept continuous where possible
Variable aOR 95% CI p value
Primigravidity 9.06 4.39–18.71 < 0.001
GA at enrollment, weeks 1.24 1.02–1.50 0.03
Any symptomatic malaria during preg-
nancy
1.88 0.82–4.32 0.14
GA of first documented infection, weeks 1.06 0.97–1.16 0.19
Total number of times parasitaemia 
detected in pregnancy
2.21 1.67–2.93 < 0.001
Table 4 Predictors of placental malaria stratified by gravidity
GA gestational age
Statistically significant p values (< 0.05) are indicated in italics
Multivariate binary logistic regression using placental malaria as the main outcome were performed and were adjusted for GA at study enrollment, GA of first 
documented infection, and total number of malaria infections (symptomatic and/or asymptomatic) in pregnancy. Variables were kept continuous where possible
Variable Primigravid (N = 87) Multigravid (N = 141)
aOR 95% CI p value aOR 95% CI p value
GA at enrollment, weeks 1.84 1.21–2.78 < 0.01 1.12 0.88–1.44 0.36
Any symptomatic malaria in pregnancy 0.57 0.14–2.38 0.44 2.89 1.05–7.95 0.04
GA of first documented infection, weeks 0.82 0.67–1.01 0.06 1.12 1.02–1.24 0.02
Total number of times parasitaemia detected in 
pregnancy
2.70 1.44–5.06 < 0.01 2.30 1.65–3.23 <0.001
Fig. 4 Frequency of infection by malaria status and gravidity. a Shows the frequency of malaria infection by malaria status (no placental malaria 
versus placental malaria) for all women. b Shows these data for primigravid women, while c shows these data for multigravida women. Each 
triangle represents one woman. Mean and 95% CI are represented with error bars. p values are two-way and calculated with Chi squared analysis
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Clinical implications
Previous studies exploring the impact of timing of 
malaria infection during pregnancy have been mixed, and 
few prior studies have examined the relationship between 
timing of infection in pregnancy and development of pla-
cental malaria despite the well-established association of 
placental malaria with increased adverse obstetric out-
comes [10, 19, 20]. Several studies have found increased 
rates of SGA [21], decreased birthweight [22, 23], and 
decreased fetal growth velocity [24] with early malaria 
infection while others have found more significant detri-
mental effects on fetal growth with infection in the sec-
ond or third trimesters [25] and/or at delivery [26, 27].
Additionally, several studies found a negative impact on 
fetal growth with both early and late infection [28–31]. 
Malaria infection in the third trimester and/or at delivery 
has also been associated with increased risk of preterm 
birth [21, 30]. Heterogeneity in the study designs, popu-
lation demographics, surveillance protocols, diagnostic 
and treatment methodologies, and regional malaria char-
acteristics may explain at least some of the discrepan-
cies in these studies. Recently, an analysis of a separate 
cohort of women in Uganda found that burden of infec-
tion and timing of parasitaemia impact risk for placental 
malaria, which is consistent with the findings [32]. This 
study suggests that the importance of timing of infection 
on the development of placental malaria may vary based 
on gravidity. This finding may further explain why prior 
literature has painted an unclear picture of the impact of 
timing of infection on placental malaria.
Taken together, the results of this study have a number 
of implications for public health strategies going forward. 
Interventions aimed at preventing, identifying, and treat-
ing asymptomatic infections are likely needed to decrease 
placental malaria in primigravid women, whereas the 
magnitude of benefit in multigravid women may be less. 
Particular attention should be placed on preventing and 
treating early infections, both symptomatic malaria epi-
sodes as well as asymptomatic parasitaemia, in primi-
gravid women. A challenge will be engaging women early 
in prenatal care. Finally, interventions aimed at reducing 
the overall number of P. falciparum infections during 
pregnancy are likely to benefit all pregnant women.
Research implications
It is important to note that the LAMP results were not 
known until after delivery, and so did not impact clinical 
care. Future studies investigating the impact of treating 
Table 5 Predictors of placental malaria stratified by presence of symptoms
GA gestational age
Statistically significant p values (< 0.05) are indicated in italics
Multivariate binary logistic regression using placental malaria as the main outcome were performed and were adjusted for GA at study enrollment, GA of first 
documented infection, and total number of malaria infections (symptomatic and/or asymptomatic) in pregnancy. Variables were kept continuous where possible
Variable Any symptomatic Malaria (N = 53) Only asymptomatic parasitemia (N = 175)
aOR 95% CI p value aOR 95% CI p value
Primigravid 2.63 0.54–12.76 0.23 12.07 5.24–27.81 < 0.001
GA at enrollment, weeks 1.36 0.89–2.08 0.15 1.26 1.00–1.58 0.05
GA of first documented infection, weeks 1.13 0.99–1.23 0.07 1.01 0.90–1.13 0.83
Total number of times parasitemia detected in 
pregnancy
2.43 1.37–4.30 < 0.01 2.13 1.53–2.97 < 0.001
Table 6 Predictors of placental malaria stratified by gestational age at initial documented infection
GA gestational age
Statistically significant p values (< 0.05) are indicated in italics
Multivariate binary logistic regression using placental malaria as the main outcome were performed and were adjusted for GA at study enrollment, GA of first 
documented infection, and total number of malaria infections (symptomatic and/or asymptomatic) in pregnancy. Variables were kept continuous where possible
Variable < 14 weeks (N = 39) 14–19.9 weeks (N = 148) > = 20 weeks (N = 41)
aOR 95% CI p value aOR 95% CI p value aOR 95% CI p value
Primigravid 29.30 3.95–217.5 0.001 10.63 4.12–27.42 < 0.001 6.02 0.79–46.10 0.08
GA at enrollment, weeks 0.78 0.14–4.33 0.78 1.58 1.19–2.09 0.002 1.14 0.77–1.67 0.51
Any symptomatic malaria in pregnancy 1.44 0.12–16.71 0.77 1.92 0.67–5.52 0.23 9.90 0.96–102.48 0.06
Total number of times parasitaemia 
detected in pregnancy
1.22 0.65–2.30 0.54 2.63 1.80–3.87 < 0.001 5.61 1.59–19.78 < 0.01
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based on prenatal surveillance for asymptomatic infec-
tions may improve outcomes, particularly in primigravid 
women who are of highest risk for adverse outcomes. 
Also, the effect of parasite density during pregnancy can-
not be evaluated with LAMP, which is reported as posi-
tive or negative detection of parasite nucleic acid in the 
sample. These are important areas of future study.
Strengths and limitations
There were many important strengths of this study 
including the longitudinal, prospective design, sono-
graphically confirmed pregnancy dating, and rigorous 
screening protocol for both symptomatic and asympto-
matic malaria infection throughout pregnancy. Addition-
ally, examination of the placentas for evidence of malaria 
was undertaken by three different methods: placental 
blood smear, placental blood LAMP, and histopathol-
ogy. Although the aforementioned strategy for placen-
tal analyses allowed for detection of microscopic as well 
as submicroscopic placental infection, histopathology 
was the most comprehensive method for diagnosis, as it 
also assessed for past placental malaria. Placental blood 
LAMP detected one additional case, but the overall ben-
efit is unknown at this time.
There are several limitations of the study to acknowl-
edge. Firstly, patients were enrolled between 12 and 
20 weeks gestation, so details of malaria exposure in the 
first trimester are not known. The high proportion of 
patients with positive LAMP at enrollment, however, sug-
gests widespread early exposure. Additionally, although 
monthly LAMP screening was performed throughout 
pregnancy, some malaria infections—particularly asymp-
tomatic infections—that occurred between screening 
points may not have been detected. Our ability to dis-
tinguish persistent from recurrent infections as well as 
more definitively ascertain the timing of placental infec-
tion was also limited as parasite genotyping studies were 
not performed. Moreover, other obstetric comorbidities 
that may affect the rate of preterm birth and SGA, such 
as preeclampsia, bleeding or placental abruption, tobacco 
use, and infection were not consistently recorded.
Conclusions
Total number of P. falciparum infections in pregnancy 
is a significant predictor of placental malaria regardless 
of gravidity, symptomatology, or timing of P. falciparum 
infection in pregnancy. The influence of gravidity on 
development of placental malaria depends on symptoma-
tology and timing of infection. Earlier initiation of an 
effective intermittent preventive therapy treatment may 
be needed to prevent placental malaria and improve birth 
outcomes, particularly in primigravid women.
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